Systematic Literature Review of Factor Xa Inhibitors in Real-World Clinical Settings

A major pharmaceutical manufacturer of a Factor Xa inhibitor partnered with Polygon Health Analytics to assess real-world safety and effectiveness of widely prescribed anticoagulants across the European Union.

Client Challenge

The client needed to understand how various Factor Xa inhibitors performed outside of clinical trials - in everyday patient care scenarios. This required a comprehensive review of independent, non-sponsored studies that covered real-world outcomes such as stroke, bleeding, and mortality.
Client Challenge

Our Research Approach

Over a 6-month engagement, our team conducted a systematic literature review spanning peer-reviewed publications from 2022 to 2024. Our scope focused on:

  • Real-world studies involving atrial fibrillation patients
  • Outcomes such as stroke, systemic embolism, major bleeding, and all-cause mortality
  • Exclusion of industry-sponsored studies to ensure unbiased results
  • Quality appraisal and standardized data abstraction methods

Key Outcomes & Industry Impact

  • Found consistent safety and efficacy profiles across major Factor Xa inhibitors.
  • Identified real-world patient trends not reflected in controlled clinical trials.
  • Results accepted for presentation at ISPOR 2025, the leading HEOR conference.
  • Equipped client with evidence-based insights for strategic planning and competitive differentiation.
Key Outcomes & Industry Impact
"I am very happy with the Polygon Health Analytics team's performance. They listen to clients' needs and deliver promptly and with high quality. I will definitely work with them more in the future."
Lisa
Director of Global HEOR